Cadila Healthcare Ltd reply to clarification sought by the exchange
The Exchange had sought clarification from Cadila Healthcare Ltd with reference to the media report titled, "Vietnam Bans 39 Indian Drug Cos for Violating Quality Standards." Cadila Healthcare Ltd response is enclosed. Clarification sought from Cadila Healthcare Ltd
The Exchange has sought clarification from Cadila Healthcare Ltd with respect to news article appearing in Economic Times on November 23, 2016 titled "Vietnam Bans 39 Indian Drug Cos for Violating Quality Standards." The reply is awaited. Zydus Cadila Gets USFDA Nod For Anti-Infections Tablets
Zydus Cadila has received final approval from the US health regulator to market its Metronidazole tablets used for the treatment of infections caused by bacteria or parasites. Zydus receives final approval from the USFDA for Metronidazole Tables
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated November 21, 2016 titled "Zydus receives final approval from the USFDA for Metronidazole Tables". Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Pankaj R Patel has submitted the disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 Outcome of Board Meeting - Scheme of Arrangement
Cadila Healthcare Ltd has informed BSE that the Board of Directors of Cadila Healthcare Limited ('Company') at its meeting held on November 17, 2016, has considered and approved the Scheme of Arrangement between Cadila Healthcare Limited and Zydus Healthcare Limited and their respective shareholders and creditors ["Scheme"] under sections 391 to 394 of the Companies Act, 1956. Zydus Healthcare Limited is a wholly owned subsidiary of the Company.... Cadila develops India's first virus like particle vaccine for treating flu
CPL Biologicals, which has developed the vaccine, is a JV between Cadila and US-based Novavax Presentation
Cadila Healthcare Ltd has informed BSE that the Company is going to participate in IDFC Investor Conference scheduled to be held on November 16, 2016. The presentation to be made to the investors is enclosed. Zydus To Present New Scientific Data of Investigational Saroglitazar at the 2016 AASLD Liver Meeting in Boston, USA
Cadila Healthcare Ltd has submitted to BSE a copy of Press Release dated October 31, 2016 titled ''Zydus To Present New Scientific Data of Investigational Saroglitazar at the 2016 AASLD Liver Meeting in Boston, USA".
Cadila Healthcare profit falls 29% to Rs337.6 crore
Cadila Healthcare's revenue rose to Rs2,403.5 crore in September quarter from Rs2,394.9 crore a year ago